AstraZeneca's Antibody Cocktail Reduces Risk of Severe COVID-19, Death, Developer Says

LONDON (Sputnik) – An experimental long-acting combo antibody therapy developed by AstraZeneca has helped cut the risk of severe COVID-19 disease or death compared to placebo in non-hospitalised patients with mild-to-moderate symptoms of the disease, the UK-Swedish pharmaceutical company said on 11 October.